论文部分内容阅读
肿瘤的分子靶向治疗是近年发展起来的一种全新治疗方向。表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)治疗晚期非小细胞肺癌,已取得一定疗效。全文对EGFR-TKI耐药的有关机制研究作一综述。
Molecular targeted therapy of tumors is a new treatment direction developed in recent years. Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment of advanced non-small cell lung cancer, has achieved some effect. The article reviews the mechanism of EGFR-TKI resistance.